Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 2, 2003, Pages 167-174

  Schroeder, Patricia E ^a   Jensen, Peter Buhl ^b   Sehested, Maxwell ^c   Hofland, Kenneth Francis ^b   Langer, Seppo W ^b   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c FINSEN LABORATORY   (Denmark)

Author keywords

ADR 925; Dexrazoxane; Doxorubicin; Etoposide; Metabolism

Indexed keywords

1,2 PROPANEDIAMINE N,N' DIACETAMIDE N,N' DIACETIC ACID; CARBOPLATIN; CISPLATIN; CLEMASTINE FUMARATE; ETOPOSIDE; METHYLPREDNISOLONE SODIUM SUCCINATE; NIZATIDINE; RAZOXANE; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; FEMALE; FLUORESCENCE; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROLYSIS; IN VIVO STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; ETHYLENEDIAMINES; ETOPOSIDE; FEMALE; GLYCINE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RAZOXANE;

EID: 0042830919     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0619-7     Document Type: Article

References (43)

1. Buss JL, Hasinoff BB (1993) The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes. Agents Actions 40:86-95
2. Dawson KM (1975) Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem Pharmacol 24:2249-2253
3. Diop NK, Vitellaro LK, Arnold P, Shang M, Marusak RA (2000) Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J Inorg Biochem 78:209-216
4. Earhart RH, Tutsch KD, Koeller JM, Rodriguez R, Robins HI, Vogel CL, Davis HL, Tormey DC (1982) Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients. Cancer Res 42:5255-5261
5. Gianni L, Zweier JL, Levy A, Myers CE (1985) Characterization of the cycle of iron-mediated electron transfer from adriamycin to molecular oxygen. J Biol Chem 260:6820-6826
6. Hasinoff BB (1989) The interaction of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane), its hydrolysis product ICRF-198, and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin. Agents Actions 26:378-385
7. Hasinoff BB (1989) Self-reduction of the iron(III)-doxorubicin complex. Free Radic Biol Med 7:583-593
8. Hasinoff BB (1990) The hydrolysis-activation of the doxorubicin cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane). Drug Metab Dispos 18:344-349
9. 3+-doxorubicin complex undergoing self-reduction by its α-ketol group. Biochem Cell Biol 68:1331-1336
10. Hasinoff BB (1993) Enzymatic ring-opening reactions of the chiral cardioprotective agent (+)(S)-ICRF-187 and its (-)(R)-enantiomer ICRF-186 by dihydropyrimidine amidohydrolase. Drug Metab Dispos 21:883-888
11. Hasinoff BB (1994) An HPLC and spectrophotometric study of the hydrolysis of ICRF-187 (dexrazoxane, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane) and its one-ring opened intermediates. Int J Pharm 107:67-76
12. Hasinoff BB (1994) Pharmacodynamics of the hydrolysis-activation of the cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. J Pharm Sci 83:64-67
13. Hasinoff BB (1994) Stereoselective hydrolysis of ICRF-187 (dexrazoxane) and ICRF-186 by dihydropyrimidine amidohydrolase. Chirality 6:213-215
14. Hasinoff BB (1998) Chemistry of dexrazoxane and analogues. Semin Oncol 25 [Suppl 10]:3-9
15. Hasinoff BB, Aoyama RG (1999) Relative plasma levels of the cardioprotective drug dexrazoxane and its two active ring-opened metabolites in the rat. Drug Metab Dispos 27:265-268
16. Hasinoff BB, Reinders FX, Clark V (1991) The enzymatic hydrolysis-activation of the adriamycin cardioprotective agent (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane. Drug Metab Dispos 19:74-80
17. Hasinoff BB, Venkataram S, Singh M, Kuschak TI (1994) Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte. Xenobiotica 24:977-987
18. Hasinoff BB, Kuschak TI, Yalowich JC, Creighton AM (1995) A QSAR study comparing the cytotoxicity and DNA topoisomerase II inhibitory effects of bisdioxopiperazine analogs of ICRF-187 (dexrazoxane). Biochem Pharmacol 50:953-958
19. Hasinoff BB, Yalowich JC, Ling Y, Buss JL (1996) The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells. Anticancer Drugs 7:558-567
20. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ (1998) Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr Med Chem 5:1-28
21. Herman EH, Ferrans VJ (1993) Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity. Cancer Chemother Pharmacol 32:445-449
22. Herman EH, Ferrans VJ (1998) Preclinical animal models of cardiac protection from anthracycline induced cardiotoxicity. Semin Oncol 25 [Suppl 10]:15-21
23. Herman EH, El-Hage AN, Ferrans VJ, Witiak DT (1983) Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters. Res Commun Chem Pathol Pharmacol 40:217-231
24. Hochster HS (1998) Clinical pharmacology of dexrazoxane. Semin Oncol 25 [Suppl 10]:37-42
25. Hochster H, Liebes L, Wadler S, Oratz R, Wernz JC, Meyers M, Green M, Blum RH, Speyer JL (1992) Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst 84:1725-1730
26. Holm B, Jensen PB, Sehested M (1996) ICRF-187 rescue in etoposide treatment in vivo. A model targeting high dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol 38:203-209
27. Holm B, Sehested M, Jensen PB (1998) Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide. Clin Cancer Res 4:1367-1373
28. Huang Z-X, May PM, Quinlan KM, Williams DR, Creighton AM (1982) Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumor agent ICRF-159 and its inactive homologue ICRF-192. Agents Actions 12:536-542
29. Jakobsen P, Sorensen B, Bastholt L, Mirza MR, Gjedde SB, Mouridsen HT, Rose C (1994) The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR 529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. Cancer Chemother Pharmacol 35:45-52
30. Jensen PB, Sehested M (1997) DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol 54:755-759
31. Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, Tyurin VA, Thampatty P, Fabisiak JP (1999) Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach. Mol Pharmacol 56:494-506
32. Kagan VE, Kuzmenko AI, Tyurina YY, Shvedova AA, Matsura T, Yalowich JC (2001) Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase. Cancer Res 61:7777-7784
33. Malisza KL, Hasinoff BB (1995) Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system. Arch Biochem Biophys 321:51-60
34. Myers C (1998) The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol 25:10-14
35. Rosing H, ten Bokkel Huinink WW, van Gijn R, Rombouts RF, Bult A, Beijnen JH (1999) Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). Eur J Drug Metab Pharmacokinet 24:69-77
36. Schroeder PE, Hasinoff BB (2002) The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925. Cancer Chemother Pharmacol 50:509-513
37. Schroeder PE, Davidson JN, Hasinoff BB (2002) Dihydroorotase catalyzes the ring-opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187). Drug Metab Dispos 30:1431-1435
38. Sehested M, Jensen PB, Sorensen BS, Holm B, Friche E, Demant EJF (1993) Antagonistic effect of the cardioprotector (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) on DNA breaks and cytotoxicity induced by the topoisomerase II directed drugs daunorubicin and etoposide (VP-16). Biochem Pharmacol 46:389-393
39. Swain SM, Whaley F, Gerber MC, Ewer MS, Bianchine JR, Gams RA (1997) Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 15:1333-1340
40. Swain SM, Whaley FS, Gerber MC, Weisberg S, York M, Spicer D, Jones SE, Wadler S, Desai A, Vogel C, Speyer J, Mittelman A, Reddy S, Pendergrass K, Velez-Garcia E, Ewer MS, Bianchine JR, Gams RA (1997) Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 15:1318-1332
41. Tetef ML, Synold TW, Chow W, Leong L, Margolin K, Morgan R, Raschko J, Shibata S, Somlo G, Yen Y, Groshen S, Johnson K, Lenz HJ, Gandara D, Doroshow JH (2001) Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin Cancer Res 7:1569-1576
42. Tyurina YY, Tyurin VA, Yalowich JC, Quinn PJ, Claycamp HG, Schor NF, Pitt BR, Kagan VE (1995) Phenoxyl radicals of etoposide (VP-16) can directly oxidize intracellular thiols: protective versus damaging effects of phenolic antioxidants. Toxicol Appl Pharmacol 131:277-278
43. Usui N, Sinha BK (1990) Tyrosinase-induced free radical formation from VP-16,213: relationship to cytotoxicity. Free Radic Res Commun 10:287-293